Scarica l'app Stockscreener
20.07
4.84%
-1.02
Precedente Chiudi:
$21.09
Aprire:
$21.03
Volume 24 ore:
144.97K
Relative Volume:
0.84
Capitalizzazione di mercato:
$392.36M
Reddito:
Utile/perdita netta:
$-83.49M
Rapporto P/E:
-4.503
EPS:
-4.457
Flusso di cassa netto:
$-60.29M
1 W Prestazione:
-5.11%
1M Prestazione:
-15.21%
6M Prestazione:
-29.68%
1 anno Prestazione:
+17.03%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$19.83
$22.44
Portata 52W:
$15.52
$39.53
Tectonic Therapeutic Inc Stock (TECX) Company Profile
Nome
Tectonic Therapeutic Inc
Settore
Industria
Telefono
(339) 666-3320
Indirizzo
490 ARSENAL WAY, WATERTOWN
Compare TECX vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TECX
Tectonic Therapeutic Inc
|
20.07 | 392.36M | 0 | -83.49M | -60.29M | -4.457 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tectonic Therapeutic Inc Stock (TECX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-12 | Iniziato | UBS | Neutral |
| 2026-05-26 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2026-04-14 | Iniziato | Stifel | Buy |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-09-03 | Iniziato | Oppenheimer | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-04-21 | Iniziato | Mizuho | Outperform |
| 2024-11-20 | Iniziato | Raymond James | Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-06-26 | Iniziato | Piper Sandler | Overweight |
| 2024-06-24 | Iniziato | TD Cowen | Buy |
| 2023-12-18 | Downgrade | Mizuho | Buy → Neutral |
| 2022-01-05 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-06-27 | Iniziato | Mizuho | Buy |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-17 | Iniziato | H.C. Wainwright | Buy |
| 2018-07-16 | Iniziato | Wedbush | Outperform |
| 2018-07-16 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Tectonic Therapeutic Inc Borsa (TECX) Ultime notizie
Form 4 Tectonic Therapeutic Inc: Marc Schwabish (Chief Business Officer) For: 25 September - Investing.com Nigeria
Form 4 Tectonic Therapeutic Inc: Alise Reicin (Director, CEO) For: 25 September - Investing.com Nigeria
Form 4 Tectonic Therapeutic Inc: Marc Schwabish (Chief Business Officer) For: 25 September - Investing.com UK
After 525 shares were withheld for taxes, Tectonic Therapeutic (TECX)'s medical chief holds 67,157 shares. - Stock Titan
An officer holds 44,903 shares after Tectonic Therapeutic (TECX) withholds 411 for taxes. - Stock Titan
After 520 shares were withheld for taxes, Tectonic Therapeutic (TECX) CFO holds 58,024 shares. - Stock Titan
493 shares are proposed for sale by officer Peter McNamara at Tectonic Therapeutic (TECX). - Stock Titan
Oppenheimer reiterates Tectonic Therapeutics stock rating on TX2100 data - Investing.com
A rare vascular disorder has no approved therapies. An experimental treatment was generally safe in healthy volunteers. - Stock Titan
Tectonic Therapeutic, Inc.Common Stock (NQ: TECX - The Chronicle-Journal
Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare - Yahoo Finance
Tectonic Therapeutic CFO Lochner Daniel Receives 24,250 Derivative Securities Award - Kalkine Media
Tectonic Therapeutic (TECX) ties CFO option grant to 42-month vesting schedule - Stock Titan
Tectonic Therapeutic (TECX) grants CEO 69,250 stock options with extended vesting - Stock Titan
Tectonic Therapeutic (TECX) awards CBO 17,750 stock options - Stock Titan
Tectonic Therapeutic (TECX) grants 24,250 options to its CMO - Stock Titan
Stock-option grant gives Tectonic Therapeutic (TECX) CSO 21,000 rights to buy shares - Stock Titan
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference - GlobeNewswire
Tectonic Therapeutic advances TX45 trial with s... - pluang.com
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case - Seeking Alpha
Tectonic Therapeutic Loses US$152m Market Value But Insiders See Windfall Of US$72k - simplywall.st
Tectonic (NASDAQ: TECX) ex-director lines up another stock sale - Stock Titan
Mizuho Securities Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $85 - Moomoo
Tectonic Therapeutic (NASDAQ: TECX) ex-director to sell 10,200 shares - Stock Titan
Tectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Zacks Research - MarketBeat
Tectonic Therapeutic (NASDAQ:TECX) Trading 5.6% HigherShould You Buy? - MarketBeat
TECX Q2 2026 Earnings: Narrower-than-Expected Loss Lifts Shares 2.74%Earnings Surprise Report - vinanet.vn
Tectonic Therapeutic CSO McNamara sells $1,505 in shares - Investing.com
Tectonic Therapeutic CSO McNamara sells $1,505 in shares By Investing.com - Investing.com India
Tectonic Therapeutic CSO McNamara sells $1,505 in shares By Investing.com - Investing.com UK
Tectonic Therapeutic CSO McNamara sells $1,505 in shares - Investing.com
TECX (TECX) insider plans 129-share sale and notes prior 10b5-1 trade - Stock Titan
Tectonic Therapeutic (NASDAQ:TECX) Trading Up 13.3%Here's What Happened - MarketBeat
Truist Financial Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
Tectonic Therapeutic (NASDAQ:TECX) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Tectonic Therapeutic Inc (TECX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tectonic Therapeutic (NASDAQ:TECX) Announces Earnings Results, Beats Estimates By $0.17 EPS - MarketBeat
TECX Maintained by Wells Fargo -- Price Target Lowered to $93.00 - GuruFocus
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76 - Moomoo
Wells Fargo & Company Issues Pessimistic Forecast for Tectonic Therapeutic (NASDAQ:TECX) Stock Price - MarketBeat
Tectonic Therapeutic, Inc. (TECX) Investor Outlook: Exploring A 159.58% Potential Upside - DirectorsTalk Interviews
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
TECX Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Pipeline Remains the FocusEarnings Revision Report - vinanet.vn
Tectonic Therapeutic, Inc. Stock 12‑Month Price Target Cut to $77.56, Implies 157% Upside - TradingView
Tectonic Therapeutic Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Tectonic Therapeutic, Inc. 2Q 2026: Net loss $22.3M, EPS $(1.18) — 10-Q Summary - TradingView
TECX: TX45 Phase 2 trial enrollment completed; topline results expected Q1 2027 - TradingView
Tectonic Therapeutic reports Q2 net loss $22.3M, cash $227.1M; TX45 enrollment complete - TradingView
Press Release: Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights - Moomoo
Tectonic Therapeutic Inc Azioni (TECX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tectonic Therapeutic Inc Azioni (TECX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PETER MCNAMARA | Officer |
Sep 30 '26 |
Proposed Sale |
23.34 |
493 |
11,507 |
0 |
| TERRANCE MCGUIRE | Former Director |
Aug 27 '26 |
Proposed Sale |
36.83 |
7,513 |
276,718 |
0 |
| McNamara Peter | Chief Scientific Officer |
Aug 25 '26 |
Option Exercise |
14.71 |
43 |
633 |
55,328 |
| McNamara Peter | Chief Scientific Officer |
Aug 25 '26 |
Sale |
36.52 |
43 |
1,570 |
55,285 |
| TERRANCE MCGUIRE | Former Director |
Aug 21 '26 |
Proposed Sale |
37.61 |
10,200 |
383,671 |
0 |
| PETER MCNAMARA | Officer |
Aug 12 '26 |
Proposed Sale |
31.87 |
129 |
4,111 |
0 |
| McNamara Peter | Chief Scientific Officer |
Aug 12 '26 |
Sale |
35.00 |
43 |
1,505 |
55,285 |
| McNamara Peter | Chief Scientific Officer |
Aug 12 '26 |
Option Exercise |
14.71 |
43 |
633 |
55,328 |
| PETER MCNAMARA | Officer |
Jun 30 '26 |
Proposed Sale |
33.09 |
172 |
5,691 |
0 |
| McNamara Peter | Chief Scientific Officer |
Jun 30 '26 |
Option Exercise |
14.71 |
172 |
2,530 |
55,457 |
3.09%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):